Fairman Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fairman Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.65K	Hold	11	–	–	﹤0.01%	269
2026 Q1	$2.08K	Hold	11	–	–	﹤0.01%	281
2025 Q4	$1.87K	Buy	+11	New	+$1.69K	﹤0.01%	290

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Fairman Group's JAZZ Position: Q2 2026 in Review

Fairman Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 11 shares worth $2.65K. The position accounts for ﹤0.01% of the portfolio, ranked #269.

Fairman Group first reported a position in JAZZ in Q4 2025 and has held it in 3 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Fairman Group held 11 shares of Jazz Pharmaceuticals worth $2.65K as of Q2 2026.
Fairman Group left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Fairman Group's portfolio in Q2 2026, its #269 holding.
Fairman Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Fairman Group's 13F filing for Q2 2026, filed 4 Aug 2026.